drugset / Trial / NCT00790868

Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder

NCT00790868

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a 5-year double blind, randomized, controlled, trial conducted at three treatment sites, aimed at showing the acute and longer-term effects of DCS augmentation of exposure-based CBT for panic disorder relative to placebo augmentation. By demonstrating that DCS can enhance the results of even a brief treatment strategy, the investigators are seeking to validate an approach that fits well with the practice limitations and applications of CBT in effectiveness studies.

Timeline

Start
2008-04
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cycloserine Small molecule 50 mg

Indications